Looks like Glaxo are in a unique position to be able to negotiate vaccine returns in return for increased stockpiling of an antiviral - Relenza.
Roche don't have this luxury because of the resistance issues with Tamiflu and the obvious growing concerns amongst governments.
I wonder whether Glaxo will soon be able to negotiate (in advance) similar sale/return deals (or Relenza/Lani) once/if they secure Lani licensing?
Now it is just a production issue for Glaxo.
Be interesting to hear whether all this upside will be discussed in Glaxo's Q1 report in 3 weeks time (28th April). During the last quarterly webcast, despite Relenza being one of their top selling individual products, there were no additional references to it. This time round, I imagine there will be too much upside around Relenza/Biota for Andrew Witty not to reference it.
- Forums
- ASX - By Stock
- BTA
- new uk deal for relenza
new uk deal for relenza, page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
Previous Video
Next Video
SPONSORED BY The Market Online